Adam Lenkowsky, Executive Vice President, Chief Commercial Officer at Bristol Myers Squibb, shared a post on LinkedIn:
“I’m pleased to share an important step forward in our work to increase transparency and expand access for patients – especially those navigating coverage gaps or paying out of pocket.
Today we announced a new collaboration between the BMS-Pfizer Alliance and Mark Cuban Cost Plus Drug Company to expand options for cash‑paying patients to access an oral anticoagulant millions of American patients rely on each day.
It is critical that we continue to seek new ways to support patients who need our medicines, and we’re proud to build on our direct-to-patient offerings with this new collaboration.”
Other articles featuring Adam Lenkowsky on OncoDaily.